This study compared 2groups of participant s, children and adolescents aged 6 to 
under 18 years and adults aged 18 to under 65 years, to find out if participant s given 
13vPnC were able to make antibodies that recognize 13 common types of 
S.pneumoniae. The researchers also wanted to see if the participants had any safety
issues in the month after having the 13vPn Cvaccine.  The study participants were all 3Japanese people with illnesses that mean they are more likely to get pneumococcal 
disease.
All participants in this study received a single dose of 13vPnC on Day 1 at the start of 
the study .
4While participant swere only in the study for approximately 1month, the entire study 
took approximately 4months to complete.  The sponsor ran this study at 8locations 
across Japan.   It began 12July2018 and ended 16November 2018 .  31boys and 
22girls aged 7 to 17 year s as well as 76 men and 77women aged 18 to 64years 
participated.  All of the 206 participant s were between the ages of 7and 64 years .
Participant s were given a single dose of the 13vPnC vaccine .  Of the 206participant s 
who started the study, all 206 finished the study and all were asked to write down if 
they had experienced anyreaction sto the 13vPnC vaccine .
When the study ended in November 2018 , the Sponsor began reviewing the 
infor mation collected.  The Sponsor then cr eated a report of the result s. This is a 
summary of that report.